BIIB

Biogen Inc

215.39

Jul 02 • 02:48PM ET +5.65 (2.69%)

Healthcare Drug Manufacturers - General USA Large NASD

Peers: AMGN GILD REGN VRTX ALNY ARGX BMY LLY MRK PFE

| Held by: VTI VOO VO IVV SPY VTV IBB XLV RSP VOE

Scroll to Statements

Index	S&P 500
Market Cap	31.80B
Enterprise Value	34.08B
Income	1.37B
Sales	9.60B
Book/sh	126.37
Cash/sh	29.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	7500
IPO	Sep 17, 1991

P/E	23.12
Forward P/E	13.20
PEG	2.11
P/S	3.31
P/B	1.70
P/C	7.43
P/FCF	13.12
EV/EBITDA	11.02
EV/Sales	3.55
Quick Ratio	2.41
Current Ratio	3.06
Debt/Eq	0.35
LT Debt/Eq	0.35
Option/Short	Yes / Yes

EPS (ttm)	9.32
EPS next Y	16.32
EPS next Q	3.20
EPS this Y	-4.98%
EPS next Y	12.42%
EPS next 5Y	6.24%
EPS past 3/5Y	-25.04% -18.74%
Sales past 3/5Y	0.35% -5.06%
EPS Y/Y TTM	-7.88%
Sales Y/Y TTM	2.11%
EPS Q/Q	31.24%
Sales Q/Q	2.88%
Earnings	Apr 29 BMO
EPS/Sales Surpr.	16.91% 8.35%

Insider Own	0.89%
Insider Trans	-0.26%
Inst Own	99.63%
Inst Trans	-2.17%
ROA	4.77%
ROE	7.70%
ROIC	5.44%
Gross Margin	66.29%
Oper. Margin	23.87%
Profit Margin	14.29%
SMA20	6.64%
SMA50	10.03%
SMA200	21.26%
Trades

Shs Outstand	147.60M
Shs Float	146.32M
Short Float	3.55%
Short Ratio	4.30
Short Interest	5.19M
52W High	219.72 -1.97%
52W Low	121.05 77.93%
Volatility	3.83% 3.24%
ATR (14)	6.70
RSI (14)	64.44
Beta	0.17
Rel Volume	0.57
Avg Volume	1.21M
Volume	567,734

Perf Week	6.65%
Perf Month	14.07%
Perf Quarter	17.20%
Perf Half Y	22.10%
Perf YTD	22.39%
Perf Year	61.72%
Perf 3Y	-24.38%
Perf 5Y	-38.23%
Perf 10Y	-4.58%
Recom	2.00
Target Price	221.21
Prev Close	209.74
Price	215.39
Change	2.69%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-26	Upgrade	Needham	Hold → Buy	$255
May-15-26	Resumed	Evercore ISI	Outperform
Apr-22-26	Upgrade	UBS	Neutral → Buy	$225
Apr-20-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$250
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight	$214
Feb-20-26	Initiated	Barclays	Equal Weight	$185
Feb-09-26	Reiterated	H.C. Wainwright	Buy	$194 → $228
Jan-07-26	Resumed	UBS	Neutral	$185
Dec-10-25	Downgrade	HSBC Securities	Hold → Reduce	$143
Nov-06-25	Upgrade	Stifel	Hold → Buy	$202
Sep-25-25	Initiated	Jefferies	Buy	$190
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180

Show Previous Ratings

Jun-29-26 07:42AM	Biogen trims Apellis pipeline and R&D team after $5.6bn takeover (Pharmaceutical Technology)
06:59AM	Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen (GlobeNewswire)
Jun-26-26 04:30PM	Biogen Inc. stock outperforms competitors on strong trading day (MarketWatch) +6.97%
01:49PM	Lilly, J&J and AbbVie Hit New Highs (GuruFocus.com)
Jun-19-26 05:48AM	Biogen to acquire RayThera for up to $1bn (Pharmaceutical Technology)
09:40AM	Loading…
Jun-18-26 09:40AM	Biogen acquires RayThera in deal worth up to $1 billion (Quartz)
07:12AM	Biogen adds more immune drugs in $1B buyout of secretive startup RayThera (BioPharma Dive)
Jun-17-26 08:03PM	BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal (Stocktwits)
06:59PM	Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. (GlobeNewswire)
Jun-16-26 06:18PM	Acumen Nominates 2 Therapies to Treat Alzheimers Disease (Exec Edge)
Jun-05-26 06:05AM	Biogen's salanersen gains FDA breakthrough therapy designation for SMA (Pharmaceutical Business Review)
Jun-04-26 07:30AM	Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (GlobeNewswire)
01:00AM	EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus (GlobeNewswire)
Jun-03-26 07:30AM	Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses (GlobeNewswire)
03:30AM	Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick. (Barrons.com)
03:15AM	Loading…
03:15AM	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors (TMX Newsfile)
Jun-01-26 01:30AM	UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus (GlobeNewswire)
May-28-26 04:01PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in June (Business Wire)
May-22-26 06:46AM	Parkinsons drug from Biogen, Denali comes up short (BioPharma Dive)
May-21-26 07:03PM	BIIB, DNLI Stocks Edge Lower After Hours: Parkinsons Drug Misses Key Goals In Trial (Stocktwits)
06:00PM	Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease (GlobeNewswire)
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
May-15-26 09:45AM	Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls (The Fly)
07:44AM	Biogen completes $5.3B Apellis Pharmaceuticals acquisition (Quartz)
May-14-26 07:19PM	Biogen Shares Jump 10% After Advancing Alzheimer's Tau Drug (GuruFocus.com) -6.43%
04:30PM	Biogen Inc. stock underperforms Thursday when compared to competitors (MarketWatch)
01:03PM	Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery. (Investor's Business Daily)
10:08AM	Biogen Shares Surge After Positive Mid-Stage Alzheimers Trial Results (InvestorsHub)
10:07AM	Biogen Stock Falls on Alzheimer's Drug Trial Miss (The Wall Street Journal)
09:07AM	Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway. (Barrons.com)
08:35AM	Loading…
08:35AM	Biogen Completes Acquisition of Apellis Pharmaceuticals (GlobeNewswire)
07:40AM	Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimers (Investing.com)
06:59AM	Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease (GlobeNewswire)
May-08-26 06:07AM	FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended (BioPharma Dive)
02:30AM	Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease (GlobeNewswire)
May-07-26 06:01PM	Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600 (PR Newswire)
04:01PM	Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
May-01-26 06:51AM	Bristol Myers legacy lift, Biogens blue skies and Regenerons murky outlook (BioPharma Dive)
Apr-30-26 04:01PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates (Business Wire)
03:06AM	Biogen Inc (BIIB) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ... (GuruFocus.com)
Apr-29-26 12:48PM	Biogen Inc. Q1 2026 Earnings Call Summary (Moby) +6.00%
07:25AM	Biogen Updates 2026 Guidance (RTT News)
07:02AM	Biogen Lowers 2026 Earnings Outlook (The Wall Street Journal)
06:42AM	Biogen shares rise after Q1 beat; full-year profit outlook slashed (Investing.com)
06:04AM	Biogen Walloped Wall Street's First Quarter Views; Here's What Happened (Investor's Business Daily)
Apr-27-26 05:22AM	Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. (Barrons.com)
Apr-24-26 11:54AM	Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal (Pharmaceutical Technology)
Apr-22-26 01:15PM	Biogen upgraded by UBS on slew of pipeline catalysts going into 2027 (Proactive)
10:20AM	UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts (Investing.com)
09:35AM	Airbnb upgraded, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Apr-20-26 09:33AM	Qorvo downgraded, Ulta Beauty upgraded: Wall Street's top analyst calls (The Fly)
07:30AM	Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region (GlobeNewswire)
Apr-18-26 09:00AM	These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated. (MarketWatch)
Apr-16-26 07:00AM	Replimune cuts staff; MeiraGTx reacquires eye gene therapy (BioPharma Dive)
Apr-14-26 09:53AM	Tesla upgraded, AppLovin initiated: Wall Street's top analyst calls (The Fly)
Apr-08-26 04:01PM	Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
05:37AM	Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs expected study failure (BioPharma Dive)
Apr-07-26 04:01PM	Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors (Business Wire)
12:01AM	Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal (The Daily Upside)
Apr-03-26 06:10PM	Where the New Houses Are-and What That Says About Growth (Barrons.com)
Apr-01-26 01:15PM	Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets (BioPharma Dive)
09:46AM	Disney upgraded, Nike downgraded: Wall Street's top analyst calls (The Fly)
07:36AM	Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout (Pharmaceutical Technology)
Mar-31-26 08:00PM	The Year Is Off to the Strongest Start for Big Deals Ever (The Wall Street Journal)
05:46PM	Big Drug Companies Hunting for Deals Are Lowering Their Sights (The Wall Street Journal)
05:11PM	Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on Announcement (GuruFocus.com)
02:43PM	Nasdaq shoots higher, Dow adds momentum as Trump looks for end to war (Proactive)
12:20PM	Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio (Proactive)
11:27AM	Nvidia invests $2B in Marvell, Eli Lilly to buy drugmaker Centessa (Yahoo Finance Video)
09:47AM	Stocks to Watch Tuesday: McCormick, Unilever, Marvell, Centessa, Apellis (The Wall Street Journal)
09:41AM	Why This Pharma Stock More Than Doubled Today (Barrons.com)
09:07AM	Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars (Investor's Business Daily)
08:07AM	Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases (MarketWatch)
07:44AM	Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion (The Wall Street Journal)
06:59AM	Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology (GlobeNewswire)
Mar-30-26 04:01PM	Treasuries Climb as Powell Eases Fed-Hike Jitters: Markets Wrap (Bloomberg)
12:11PM	Biogen high-dose Spinraza approval seen supporting long-term growth (Proactive)
11:00AM	United rises on IPF data; Biogen scores positive lupus data and an approval (BioPharma Dive)
07:30AM	FDA Approves New High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy (GlobeNewswire)
Mar-28-26 03:00PM	Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity (GlobeNewswire)
Mar-20-26 12:05PM	Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 (GlobeNewswire)
Mar-19-26 07:30AM	Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-11-26 01:51PM	Biogen Stock: Is BIIB Outperforming the Healthcare Sector? (Barchart)
08:00AM	Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy (GlobeNewswire)
Mar-09-26 11:35PM	Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks (StockStory)
Mar-06-26 04:18PM	Biogen CEO touts new era of growth at TD Cowen as 10 Phase 3 programs near key readouts (MarketBeat)
10:26AM	LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? (Zacks)
07:39AM	Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? (Zacks)
Mar-05-26 08:36AM	What Makes Biogen (BIIB) an Attractive Long-Term Holding? (Insider Monkey)
07:30AM	Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences (GlobeNewswire)
Mar-04-26 05:06PM	The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome (Business Wire)
Mar-02-26 06:50PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
Feb-27-26 09:02AM	DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus (Zacks)
Feb-26-26 10:04PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:18AM	Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook (Zacks)
07:35AM	Is Vertex Stock Outperforming the Dow? (Barchart)
Feb-24-26 04:01PM	Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (Business Wire)
Feb-23-26 12:59PM	This Rare Disease Biotech Name Teases Around A Buy Point (Investor's Business Daily)
09:50AM	Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock (Zacks)
Feb-20-26 03:49PM	Top Analyst Reports for Philip Morris, Lockheed Martin & Danaher (Zacks)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

PresidentMr. Christopher A. Viehbacher

Executive VP & CFOMs. Robin C. Kramer

Executive VP and Head of Pharmaceutical Operations & TechnologyMs. Nicole Murphy

M.P.H.Dr. Priya Singhal M.D.

VPMr. Sean Godbout

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pangalos Menelas N	Director	Jun 09 '26	Option Exercise	0.00	2,370	0	2,370	Jun 11 05:21 PM
Keeney Adam	Head of Corporate Development	May 01 '26	Option Exercise	0.00	939	0	6,820	May 05 04:11 PM
Godbout Sean	Chief Accounting Officer	Apr 01 '26	Option Exercise	0.00	181	0	1,396	Apr 03 04:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 12 '26	Buy	195.03	3	585	19,611	Feb 17 08:16 PM
Viehbacher Christopher	President and CEO	Feb 06 '26	Option Exercise	0.00	24,461	0	36,548	Feb 10 05:06 PM
Singhal Priya	Head of Development	Feb 06 '26	Option Exercise	0.00	6,900	0	12,115	Feb 10 05:05 PM
Singhal Priya	Head of Development	Feb 09 '26	Sale	199.83	2,660	531,548	8,043	Feb 10 05:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 06 '26	Option Exercise	0.00	8,725	0	21,016	Feb 10 05:03 PM
Kramer Robin	Chief Financial Officer	Feb 06 '26	Option Exercise	0.00	5,003	0	12,535	Feb 10 05:02 PM
Keeney Adam	Head of Corporate Development	Feb 06 '26	Option Exercise	0.00	5,080	0	6,875	Feb 10 05:01 PM
Izzar Rachid	Head of Global Product Strat.	Feb 06 '26	Option Exercise	0.00	6,889	0	11,786	Feb 10 05:00 PM
Grogan Jane	Head of Research	Feb 06 '26	Option Exercise	0.00	3,258	0	4,642	Feb 10 04:59 PM
Gregory Ginger	EVP, Human Resources	Feb 06 '26	Option Exercise	0.00	7,183	0	23,491	Feb 10 04:58 PM
Godbout Sean	Chief Accounting Officer	Feb 06 '26	Option Exercise	0.00	1,079	0	1,395	Feb 10 04:56 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 06 '26	Option Exercise	0.00	9,046	0	43,321	Feb 10 04:55 PM
Singhal Priya	Officer	Feb 09 '26	Proposed Sale	199.83	2,660	531,548		Feb 09 10:14 AM
Singhal Priya	Head of Development	Jan 30 '26	Option Exercise	0.00	1,829	0	7,601	Feb 03 05:17 PM
Singhal Priya	Head of Development	Feb 02 '26	Sale	179.30	748	134,116	6,271	Feb 03 05:17 PM
Singhal Priya	Officer	Feb 02 '26	Proposed Sale	179.30	748	134,116		Feb 02 11:10 AM
Viehbacher Christopher	President and CEO	Dec 01 '25	Option Exercise	0.00	7,040	0	19,847	Dec 03 04:42 PM
Grogan Jane	Head of Research	Oct 31 '25	Option Exercise	0.00	695	0	2,128	Nov 04 04:12 PM
Godbout Sean	Chief Accounting Officer	Oct 02 '25	Option Exercise	0.00	26	0	503	Oct 06 01:00 PM
Singhal Priya	Head of Development	Aug 29 '25	Option Exercise	0.00	1,669	0	7,096	Sep 02 05:56 PM
Singhal Priya	Head of Development	Sep 02 '25	Sale	133.55	517	69,045	5,772	Sep 02 05:56 PM
Singhal Priya	Officer	Sep 02 '25	Proposed Sale	133.55	517	69,045		Sep 02 12:54 PM
Izzar Rachid	Head of Global Product Strat.	Jul 08 '25	Sale	135.00	2,223	300,105	6,330	Jul 16 05:55 PM
Izzar Rachid	Officer	Jul 08 '25	Proposed Sale	135.00	2,223	300,105		Jul 08 03:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

BIIB

Biogen Inc

Upgrade your Finviz experience